Executive moves at Merck's Healthcare business sector

18 May 2021

German pharma and life sciences firm Merck KGaA (MRK: DE) today announced changes in its operating model for its Healthcare business sector.

“Our redesigned Healthcare organization creates dedicated leadership for our strategic priorities with a focus on growth,” said Peter Guenter, a member of the executive board of Merck, and chief executive Healthcare. “Our clear intent is to bring meaningful value to more patients with our current and future portfolio,” he noted.

Given the priority of North America as a driver of future growth for Merck’s Healthcare business sector, dedicated leadership in this key market is essential. To this end, Chris Round will assume the role of president of EMD Serono, leading the US and Canada Healthcare business. Mr Round has been with the organization since 2017, previously serving as head of international and core franchises, and head of EMEA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK